ValuEngine cut shares of Puma Biotechnology (NASDAQ:PBYI) from a hold rating to a sell rating in a research note published on Wednesday morning.

Several other analysts also recently commented on PBYI. Credit Suisse Group reaffirmed an outperform rating and set a $136.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, September 27th. Citigroup reaffirmed a buy rating and set a $156.00 price objective (up previously from $114.00) on shares of Puma Biotechnology in a research report on Thursday, October 5th. JPMorgan Chase & Co. reaffirmed a buy rating and set a $131.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Stifel Nicolaus raised their price objective on shares of Puma Biotechnology from $110.00 to $130.00 and gave the stock a buy rating in a research report on Monday, October 2nd. Finally, Barclays reaffirmed a buy rating and set a $122.00 price objective (up previously from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $130.67.

Shares of Puma Biotechnology (PBYI) opened at $95.35 on Wednesday. Puma Biotechnology has a 52-week low of $28.35 and a 52-week high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the consensus estimate of ($2.50) by $0.43. The company had revenue of $6.10 million for the quarter, compared to analyst estimates of $3.78 million. During the same period last year, the business earned ($1.11) EPS. research analysts predict that Puma Biotechnology will post -8.19 earnings per share for the current year.

In related news, insider Charles R. Eyler sold 1,322 shares of Puma Biotechnology stock in a transaction on Friday, December 1st. The shares were sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 21.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. grew its position in Puma Biotechnology by 5.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares during the period. Rhumbline Advisers lifted its stake in Puma Biotechnology by 0.8% during the 2nd quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock valued at $2,948,000 after acquiring an additional 271 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Puma Biotechnology by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after acquiring an additional 437 shares in the last quarter. California Public Employees Retirement System lifted its stake in Puma Biotechnology by 0.7% during the 3rd quarter. California Public Employees Retirement System now owns 108,000 shares of the biopharmaceutical company’s stock valued at $12,933,000 after acquiring an additional 800 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its stake in Puma Biotechnology by 13.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 936 shares in the last quarter. 96.00% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Puma Biotechnology (PBYI) Cut to Sell at ValuEngine” was published by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/puma-biotechnology-pbyi-cut-to-sell-at-valuengine/1797455.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.